

MONITORING A PATIENT WITH BORDERLINE RESPONSE

George is retired and a proud grandfather of 4 who wants to be active in his family's lives. Has he achieved the optimal control of his disease?

Sokal risk score	Low risk (0.7)
Current treatment	2nd-line TKI
Length of time on current treatment	12 months
Molecular status	5% BCR-ABL1

- George's response may be plateauing. Could he be resistant?
- According to National Comprehensive Cancer Network® (NCCN®), patients with >1% to 10% BCR-ABL1 at 12 months have possible TKI resistance

LEARN ABOUT UNMET NEEDS IN CML. [VISIT OUR SITE](#)

TARGETCML

CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia V.3.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed March, 20, 2021. To view the most recent and complete version of the guideline, go online to [NCCN.org](https://www.nccn.org). NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.

 **NOVARTIS**

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2021 Novartis

3/21

111533

